TGF-b plays a dual role in epithelial carcinogenesis with the potential to either suppress or promote tumor progression. We found that levels of Smad3 mRNA, a critical mediator of TGF-b signaling, are reduced by approximately 60% in human breast cancer. We therefore used conditionally immortalized mammary epithelial cells (IMEC) of differing Smad3 genotypes to quantitatively address the Smad3 requirement for different biologic responses to TGF-b. We found that a two-fold reduction in Smad3 gene dosage led to complex effects on TGF-b responses; the growth-inhibitory response was retained, the pro-apoptotic response was lost, the migratory response was reduced, and the invasion response was enhanced. Loss of the pro-apoptotic response in the Smad3 þ/À IMECs correlated with loss of Smad3 binding to the Bcl-2 locus, whereas retention of the growth-inhibitory response in Smad3 IMECs correlated with retention of Smad3 binding to the c-Myc locus. Addressing the integrated outcome of these changes in vivo, we showed that reduced Smad3 levels enhanced metastasis in two independent models of metastatic breast cancer. Our results suggest that different biologic responses to TGF-b in the mammary epithelium are differentially affected by Smad3 dosage and that a mere two-fold reduction in Smad3 is sufficient to promote metastasis. Mol Cancer Res; 10(10); 1389-99. Ó2012 AACR.
Introduction
TGF-bs are widely expressed, pleiotropic growth factors that modulate a variety of key biologic responses. In the adult animal, the TGF-bs are important in maintaining tissue homeostasis and in orchestrating response to stress or injury, and perturbations in the TGF-b signaling pathway have been implicated in a wide variety of pathologic processes. In carcinogenesis, TGF-bs play a complex dual role in many epithelial tissues including the mammary gland, as evidenced by numerous preclinical studies and correlative clinical data (reviewed in refs. [1] [2] [3] [4] . Early in tumorigenesis, tumor-suppressive effects of TGF-bs generally dominate, involving biologic responses such as inhibition of proliferation, induction of apoptosis or replicative senescence, maintenance of genomic stability and regulation of differentiation. However, in advanced disease, resistance to the tumor-suppressive effects of TGF-b frequently develops, due to altered expression and/ or activity of components of the TGF-b signaling pathway, or to progression-related changes that specifically affect the effector arm of the tumor suppression program. At the same time, tumor cell-autonomous responses to TGF-b that promote progression, such as invasion and migration, are enhanced or unmasked by the accumulating genetic and epigenetic changes in the tumor. Furthermore, increased TGF-b in the tumor bed leads to tumor-promoting effects of TGF-b on the microenvironment, such as suppression of immunosurveillance and enhanced angiogenesis.
The canonical TGF-b signaling pathway involves TGFb-induced phosphorylation of two central mediators, Smad2 and Smad3, which translocate to the nucleus and regulate gene expression (5, 6 ). Smad3 appears to be the more important mediator in the adult organism, as Smad2 is either dispensable or actually opposes Smad3 in many biologic responses (7) (8) (9) . However, unlike Smad2, Smad3 is rarely mutated or deleted in human cancer (10) . Here, we have shown that human breast tumors have Smad3 mRNA levels that are reduced approximately 2-fold compared with the adjacent normal breast tissue. We have used a genetic approach to ask what effect this reduction in Smad3 has on TGF-b responses and tumorigenesis in the breast epithelium. Unexpectedly, we found that a mere 2-fold reduction in Smad3 significantly affected multiple TGF-b responses in vitro in a variety of different ways. In vivo, the integrated outcome of these effects was an enhancement of metastasis in two different breast cancer models.
Materials and Methods

Cell lines and genetic modification
Conditionally immortalized mouse mammary epithelial cells (IMEC) with 0, 1, or 2 alleles of Smad3 were generated by intercrossing the Smad3DelEx8 knockout mouse (11) and the H-2Kb-tsA58 transgenic "Immortomouse," which broadly expresses a temperature-sensitive SV-40 large T antigen (12) . The IMECs were generated and propagated as previously described (7) . Briefly, IMECS were expanded and propagated under permissive conditions: growth at 33 C (5% CO 2 ) in Ham's F12 medium supplemented with 10% FBS, 10 ng/mL EGF, 5 mg/mL insulin, 1 mg/mL hydrocortisone, 5 ng/mL cholera toxin, 50 mg/mL gentamycin ("complete" medium) and 30 U/mL IFN-g. For assays, cells were switched to nonpermissive conditions by growing at 37 C (5% CO 2 ) in the absence of IFN-g for 2 to 4 days before the assay, to provide sufficient time for T antigen expression to fully decay. For the Smad3 þ/À genotype that was the focus of this study, 3 independent IMEC isolates were generated: EAK4, IMEC49, and IMEC 52. Mvt-1, a metastatic mouse mammary cell line derived from a mammary tumor that arose in an MMTV-c-Myc/VEGF bitransgenic mouse (13) , was a gift of the late Dr. Robert Dickson (Georgetown University, Washington, D.C.) and was cultured at 37 C (5% CO 2 ) in Dulbecco's Modified Eagle's Media with 10% FBS. For genetic modification of the Mvt-1 line to knockdown Smad3, short hairpin RNA (shRNA) against Smad3 (5 0 -GGCCATCACCACGCA-GAAC-3 0 ) or GFP (5 0 -AAGACCCGCGCCGAGGT-GAAG-3 0 ) were cloned into the pLKO.1 lentiviral vector. To add back Smad3 to the Smad3 þ/À IMECs, human Smad3 was cloned into a modified pFUGW lentiviral backbone by Gateway recombinational cloning, with expression driven by the CMV13 promoter. A stuffer sequence was used in place of Smad3 to generate the control construct. In both cases, transduced cells were selected with puromycin for 5 days, and in vivo experiments were carried out within 3 to 5 passages. For knockdown and add-back experiments, Smad3 protein levels were quantitated by SimpleWestern (see below).
Conventional Western blot, Simple Western analyses, and zymography
Conventional Western blot analyses, and gelatin zymography to assess matrix metalloproteinase (MMP) activity, were conducted essentially as previously described (7) . For Western blot analyses of phospho-Smads, serum-starved cells were treated with 2 ng/mL TGF-b for 1 hour. For Western blot analyses of other TGF-b target proteins, serum-starved cells were treated for 24 hours. Antibodies used were as follows: Smad2, Zymed # 51-1300 or Invitrogen #511300
(1:1,000); phospho-Smad2, Cell Signaling #3108S (1:1,000); Smad3, Abcam #ab28379 (1:1,000); phosphoSmad3, Epitomics #1880-1 (1:1,000); b-actin, Sigma #A1978 (1:5,000); c-myc, Active Motif #39012 (1:500); Bcl-2, Cell Signaling (1:1,000); cleaved caspase-3, Cell Signaling #9661 (1:1,000); p15INK4B, Santa Cruz Biotechnology #sc-613 (1:1,000); and p21Cip1, Santa Cruz Biotechnology #sc-6246 (1:1,000). Membranes were blocked with 5% bovine serum albumin (Smad2) or 5% nonfat dry milk (all others).
In select cases, Smad3 protein levels were quantitated using the automated capillary-based Simon SimpleWestern System (ProteinSimple). With this technique, automation and the elimination of the blotting step allows more accurate and reproducible assessment of protein levels. 60 ng of cell lysate protein in reducing buffer with fluorescent molecular weight standards was loaded into each capillary, and proteins were separated by molecular weight through stacking and separation matrices for 45 minutes at 250 V. Proteins were immobilized to capillary walls using proprietary, photoactivated capture chemistry. Capillaries were then incubated with a blocking reagent and target proteins were immunoprobed with rabbit anti-Smad3 (Epitomics #1735-1) and anti-a-tubulin (Cell Signaling Technology #2125) primary antibodies and horseradish peroxidase-conjugated anti-rabbit secondary antibodies (Jackson ImmunoResearch). A mixture of luminol and peroxide was added, the resulting chemiluminescent signal was captured by a CCD camera, and the signal intensities were quantified and analyzed using Compass Software (ProteinSimple). During analysis, the Smad3 signal was normalized to the a-tubulin loading control in the same samples.
Quantitative real-time PCR
Real-time PCR (RT-PCR) reactions were run according to the manufacturer's instructions (Brilliant SYBR Green Master Mix, Stratagene) using a BioRad CFX96 Real Time System. Expression was normalized to either PPIA or PPIB. Supplementary Table S1 .
Smad3 expression in human breast tissues
Total RNA from tumor and normal adjacent breast tissue from 10 female patients with breast cancer was purchased from Oncomatrix Inc., and Smad3 mRNA was assessed by QRT-PCR and normalized to PPIA. Patient characteristics are given in Supplementary Table S2 . A meta-analysis to investigate the relationship of Smad3 mRNA expression to clinical parameters across 8 independent breast cancer cohorts was conducted using the online GOBO tool (http://co.bmc.lu.se/gobo; ref. 14) . For immunohistochemistry to assess which cell types in the tumor express Smad3, unstained sections of an estrogen receptor (ER)-negative, lymph node-positive, grade 2 breast cancer, and matched adjacent normal tissue from the same patient were purchased from Capital Biosciences. Immunolocalization of Smad3 using rabbit anti-Smad3 from Abcam (cat # ab28379) at 0.04 mg/mL was conducted as previously described (15) . Before immunostaining, antigen retrieval in 1 mmol/L EDTA (pH 8) was carried out at 95 o C for 10 minutes following deparaffinization of sections. A mouse embryo section was stained as a positive control, and omission of primary antibody served as the negative control.
Smad3 chromatin immunoprecipitation
Serum-starved cells were treated with 2 ng/mL TGF-b or vehicle for 1 hour, before dual cross-linking with 2 mmol/L di-(N-succinimidyl)glutarate (Thermo Scientific) and 1% formaldehyde, followed by sonication and immunoprecipitation of sonicated DNA with anti-Smad3 antibody (#28379 Chip Grade, Abcam). After immunoprecipitation, chromatin immunoprecipitation (ChIP)ed DNA was quantitated by Q-PCR. Primers (5 0 -ACAGGACTTCTGCAA-ATGCT-3 0 and 5 0 -AACCAGAGATCTCAAGAGCA-3 0 ) were used to amplify a 98-bp fragment encompassing the GC-rich repeat of the mouse Bcl-2 P2 promoter (16) . Primers (5 0 -CGACTCGCCTCACTCCAGCTC-3 0 and 5 0 -GTCCGCTCACTCCCTCTGTC-3 0 ) were designed to amplify a 175-bp fragment corresponding to the region in the mouse c-Myc gene that is homologous to the repressive Smad-binding element (RSBE) in the human c-MYC promoter (17) . Results are expressed as the fold enrichment of ChIPed DNA compared with input DNA for 3 biologic replicates, with the Smad3-null cells serving as an internal negative control for nonspecific pull-down.
Growth inhibition, apoptosis, cell migration, and invasion assays
Relative rates of proliferation of the IMEC lines were assessed by real-time imaging of cell culture confluency using an IncuCyte imaging system (Essen Instruments). Phase contrast images were taken every 3 hours over a period of 30 hours, and the culture confluency at each time point was calculated and plotted. Inhibition of cell proliferation by TGF-b was assessed by [ 3 H]-thymidine incorporation, and apoptosis was quantitated using the Cell Death Detection ELISA kit (Roche). Cell migration and invasion assays were carried out using the Transwell system without or with Matrigel, respectively (8 mm, BD Biosciences). Conditions for all assays were as previously described (7).
Tumorigenesis in transgenic and syngeneic transplant models
All animal studies were conducted under institutionally approved animal study protocols. Smad3 þ/À mice (11) were intercrossed with MMTV-PyMT transgenic mice (18) to generate oncogenically initiated cohorts that were wild-type or heterozygous for Smad3. The Smad3 þ/À mice were on an inbred, mixed C57Bl/6/BlackSwiss/129Sv background whereas the MMTV-PyMT mice were pure FVB/NJ. Tumorigenesis and metastasis in this transgenic model were assessed in the F1 offspring of the intercross to control for background strain effects. It should be noted that the overall incidence of lung metastases was lower on this mixed genetic background ($40%) than is seen with the pure FVB/N strain ($90%; ref. 18 ). This feature of the mixed background made it possible to see a stimulatory effect of the Smad3 þ/À genotype on metastasis incidence. Mice were euthanized 40 days after initial detection of a palpable mammary tumor and tissues were harvested for molecular and pathologic analysis. Lung metastases in histologic sections were enumerated by a pathologist. For the syngeneic transplant studies, 100,000 Mvt-1 cells (derived from a metastatic tumor in an MMTV-c-Myc/VEGF bitransgenic mouse and syngeneic to the FVB/N strain; ref. 13) were surgically implanted in the #4 mammary gland of 6-to 8-week-old Smad3 þ/þ or Smad3 þ/À mice that had been backcrossed for 10 generations onto the FVB/NJ background. Tumor-bearing mice were euthanized after 7 weeks, and lungs were harvested for assessment of metastatic burden as above.
Results and Discussion
Although Smad3 is rarely, if ever, deleted in human breast cancer (10), we wished to assess whether more subtle alterations in Smad3 expression levels might occur. We found that Smad3 mRNA expression was reduced in 9 of 10 cases of human breast cancer when compared with matched adjacent normal samples, for an average reduction in Smad3 of approximately 60% in the tumor (Fig. 1A and  B) . In a meta-analysis of 1,412 human breast cancer cases with Affymetrix U133A gene expression data in the GOBO database (14) , Smad3 mRNA levels were significantly lower in the highest grade (grade 2) tumors than in lower grade tumors (Fig. 1C) . Furthermore, Smad3 mRNA was also significantly lower in the poorer prognosis ER-negative breast cancers than in ER-positive tumors in the same data set (Fig. 1D) . We have previously shown that the majority of Smad3 mRNA in the mouse mammary gland is associated with the epithelial compartment (19) . To confirm the presence of Smad protein in the epithelial compartment in human breast cancer, we immunostained a matched breast cancer and adjacent normal breast tissue from the same patient. The results show that Smad3 is highly expressed in the normal ductal epithelium and that lower expression is observed in the parenchymal cells of a breast cancer from the same patient (Fig. 1E) . Together, these observations all suggest that a reduction in Smad3 levels in the tumor parenchyma might contribute to breast cancer progression. Our mRNA data are also in agreement with a previous immunohistochemical study which showed significant correlations between a decrease in Smad3 nuclear abundance and high tumor grade and hormone receptor negativity in breast cancer (20) .
To ask what effect a 2-fold reduction in Smad3 levels might have on TGF-b responses in the mammary epithelium, we generated conditionally IMECs of the 3 Smad3 genotypes, Smad3
þ/À , and Smad3 À/À (7). This genetic approach allowed us to precisely achieve a reduction in Smad3 levels (in the Smad3 þ/À IMECs) that was comparable with that seen in the human tumors. At the protein level, Smad3 expression and TGF-b-induced Smad3 phosphorylation were reduced in the Smad3 þ/À cells and completely absent in the Smad3 À/À cells, whereas Smad2 expression and activation were essentially unchanged ( Fig.  2A) . Quantitation of Smad3 protein in the Smad3 þ/À IMECs using the SimpleWestern technology showed that Smad3 protein was reduced to 47% AE 7% (n ¼ 3 independent determinations) of wild-type levels (Fig. 2B) .
Morphologically, Smad3
þ/þ and Smad3 þ/À cells showed similar, loosely organized colonies in culture (Fig. 2C) , whereas Smad3
À/À cells formed colonies with clearly defined boundaries, as seen previously (7). Proliferation rates were broadly similar between the 3 cell lines (Fig. 2D) .
We next used these cells to examine the effect of Smad3 dosage on two tumor-suppressive effects of TGF-b (cell proliferation and apoptosis), and two pro-progression responses (migration and invasion). While all responses to TGF-b were (Fig. 3A) but completely lost their pro-apoptotic response (Fig. 3B) . The loss of the proapoptotic response in the Smad3 þ/À cells was seen for 3 independent cell isolates (Fig. 3C) . To confirm that this loss was Smad3-dependent and not a result of compensatory changes in the Smad3 þ/À cells, we used lentiviral transduction to add back Smad3 to wild-type levels (Fig. 3D) . Add back of Smad3 restored the apoptotic response to TGF-b to the same level as in the Smad3 þ/þ cells (Fig. 3E) . In contrast to this pattern of either full retention (growth inhibition) or complete loss (apoptosis) of response to TGFb in the Smad3 þ/À cells, a different pattern was observed for the pro-progression responses. Smad3 þ/À cells showed a reduced migratory response to TGF-b (Fig. 3F) , whereas the invasion response in Smad3 þ/À cells was at least as strong, and often stronger, than in Smad3 þ/þ cells (Fig. 3G) . The unexpected enhancement of invasion in Smad3 þ/À cells was seen in 3 independent experiments at one or more of the two TGF-b concentrations tested (data not shown). Thus, a 2-fold reduction in Smad3 dosage can alter the outcome of TGF-b signaling in ways that differ dramatically depending on the response considered. The pattern of change in biologic responses to TGF-b at the different Smad3 levels is summarized in Table 1 .
To address why the antiproliferative and pro-apoptotic effects of TGF-b were differentially sensitive to loss of one Smad3 allele, we examined the known Smad3 targets c-Myc (17) and Bcl-2 (16, 21) . In agreement with the biologic response outcome data, TGF-b effectively suppressed c-Myc protein levels in both Smad3 þ/þ and Smad3 þ/À cells (Fig. 4A) . Expression of two other major cell-cycle-related targets of TGF-b, the cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p15INK4B, was unaffected (data not shown). In contrast to the expression pattern seen with cMyc, Bcl-2 protein was downregulated by TGF-b only in Smad3 þ/þ and not Smad3 þ/À cells (Fig. 4B) . As expected, downregulation of Bcl-2 in Smad3 þ/þ cells was associated with an increase in cleaved caspase-3, a marker of apoptosis (Fig. 4B) . Thus, TGF-b-induced repression of c-Myc and Bcl-2 shows patterns of Smad3 dependency that correlate well with the observed biologic outcomes.
We then asked whether TGF-b-induced binding of Smad3 to these target gene loci was affected by Smad3 gene dosage. TGF-b represses transcription of the human c-MYC locus via binding of Smad3 to an RSBE in the first exon (17) . By ChIP analysis, we showed strong TGF-b-induced Smad3 occupancy of the homologous region in the mouse c-Myc enhancer in both Smad3 þ/þ and Smad3 þ/À IMEC cells, consistent with the protein and biologic response data (Fig. 4C) . Transcriptional repression of the Bcl-2 locus involves Smad3 binding to a repressive GC-rich region in the first exon (16) . In contrast to results at the c-Myc locus, we found that TGF-b treatment induced Smad3 binding to the GC-rich region of the Bcl-2 enhancer only in Smad3 (Fig. 4D) . In Smad3 enhancer than the c-Myc enhancer. Thus, the reduction in Smad3 protein in the Smad3 þ/À state leads to selective loss of Smad3 from the low affinity repressive site in the Bcl-2 enhancer but retention at the higher affinity repressive site in the c-Myc enhancer. The net effect is loss of the proapoptotic response but retention of the growth-inhibitory response in Smad3 þ/À cells (schematized in Fig. 4E ). The migration and invasion responses are molecularly more complex than the growth-inhibitory and pro-apoptotic responses, involving many different molecular steps and processes. To address possible mechanisms underlying the unexpectedly enhanced invasion response to TGF-b in Smad3 þ/À cells, we first assessed MMP activity by gelatin zymography. While most MMPs were unaffected or undetectable, TGF-b induced MMP9 activity in Smad3 wildtype but not Smad3 þ/À cells, a pattern that cannot explain the enhanced invasion response (Supplementary Fig. S1 ). In some cell types, TGF-b can induce a strong EMT, which is thought to be important for invasion responses (22) . Like the majority of breast cancer cell lines (23) , the IMECs do not show a strong morphologic EMT in response to TGF-b (7). However, we tested whether TGF-b might induce any of the molecular changes characteristic of a partial EMT and whether the patterns of regulated gene expression in cells of the three different Smad3 genotypes correlated with the observed pattern of the invasion response. In a preliminary screen for effects of TGF-b on mRNA levels for Cdh1, Cdh2, Cdh3, Snail1, Snail2, Twist1, Zeb1 and Vimentin, only Cdh2 and Snail2 emerged as possible candidates with an appropriate pattern of response ( Supplementary Fig.  S2A ). Snail2 did not validate in subsequent independent experiments, but Cdh2 showed an expression pattern like that of Bcl-2, in that it was suppressed in Smad3 Supplementary Fig. S2B ). Cdh2 has been previously shown to promote invasion (24), so we hypothesize that the enhanced TGF-b-induced invasion seen in Smad3 þ/À cells likely involves a combination of selective loss of TGF-b-mediated repression of invasion-promoting components such as Cdh2, and/or selective loss of TGFb-mediated induction of inhibitors of invasion. Identification of additional contributing components will best be addressed through unbiased genome-wide approaches in future studies.
Our in vitro data suggested that reduced Smad3 levels might tip the balance of TGF-b responses in favor of tumor progression, with the apoptotic response lost and the invasion response enhanced. To address the integrated effect of the reduction in Smad3 levels on the tumorigenic process in vivo, we crossed the MMTV-PyMT transgenic mouse model of metastatic breast cancer (18) with Smad3 þ/À mice (11). As expected, Smad3 was decreased by 50% to 70% at the mRNA (Fig. 5A ) and protein ( Fig. 5B ) levels in primary tumors from MMTV-PyMT Â Smad3 þ/À mice. There was no difference in primary tumorigenesis between oncogenically initiated Smad3 þ/þ and Smad3 þ/À mice (Fig. 5C ). However Smad3 þ/À mice had a significantly higher incidence of metastases than wild-type mice (45% vs. 20%, P ¼ 0.02; Fisher exact test; Fig. 5D ). Thus, a mere 2-fold reduction in Smad3 levels can significantly enhance metastatic efficiency in vivo.
The Smad3 þ/À mouse used in the above studies was from a germline knockout model, and thus had reduced Smad3 levels in all tissues. To address whether the metastasispromoting effect of reduced Smad3 was due to the reduction of Smad3 in the tumor parenchyma or microenvironment, we used the Mvt-1 transplantable model of metastatic murine breast cancer (13) . To assess the microenvironmental contribution, Mvt-1 were orthotopically transplanted into syngeneic, immunocompetent Smad3 þ/þ and Smad3 þ/À host mice. Mvt-1 cells gave significantly increased numbers of metastases in the lungs of the Smad3 þ/À compared with Smad3 þ/þ mice (Fig. 5E ). To assess the tumor parenchymal contribution, we knocked down Smad3 levels in Mvt-1 tumor cells with shRNA (Fig. 5F ). Quantitation by Simon SimpleWestern showed that Mvt-1-shSmad3 cells had 50% less Smad3 protein than Mvt-1-shGFP control cells, so knockdown was comparable with that seen in the genetic model. We saw significantly increased metastasis in Mvt-1-shSmad3 cells compared with control Mvt-1 cells following orthotopic transplantation into Smad3 þ/þ hosts (Fig. 5G ). Together these results confirm that a reduction in Smad3 can increase metastasis in an independent breast cancer model and suggest that reduced Smad3 in both the tumor parenchyma and the tumor microenvironment can contribute independently to enhanced metastatic efficiency.
Overall, our data suggest that a mere 2-fold reduction in Smad3 levels can significantly impact on tumor progression. In this study, we looked at just four of the many biologic responses to TGF-b that are potentially relevant to tumor development. However, our results illustrate the important general principle that relatively small reductions 
in Smad3 levels can cause a spectrum of different effects on the pattern of TGF-b responses, with individual outcomes ranging from total loss of response (apoptosis), or reduction in response (migration), through no effect (growth inhibition), to enhancement of response (invasion). For the growth-inhibitory and apoptotic responses, we were able to show that the impact of Smad3 reduction on the biologic readout correlated with differences in TGF-b-induced Smad3 occcupancy at enhancer elements of key target genes for the responses. The data are consistent with a mechanism in which different target enhancers have different affinities for Smad3, such that a small reduction in Smad3 levels causes a selective loss of Smad3 from some enhancers (e.g., Bcl-2) but not from others (e.g., c-Myc). In a similar manner, activin/nodal signaling through Smad2 was recently shown to cause transcriptional activation of different sets of target genes depending on the quantitative level of Smad2 activation, thereby eliciting different biologic fates in the embryonic stem cell (21) . The integrated result of the various, sometimes opposing, effects of reduced Smad3 dosage on TGF-b responses in vivo is likely to be highly dependent on the specific constellation of TGF-b responses that are engaged and dominant in a given context. Here, we have shown that the net outcome of Smad3 reduction in the mammary epithelium is an enhancement of metastatic progression, at least in the context of oncogenic activation of the Src (PyMT model) or Myc (Mvt-1 model) pathways. However, it remains to be seen how general this phenomenon is. In the 7,12-dimethylbenz (a)anthracene (DMBA)/12-O-tetradecanoylphorbol-l3-acetate (TPA)-initiated skin carcinogenesis model, global deletion of one allele of Smad3 resulted in a significant decrease in primary tumor incidence, although effects on metastasis were not reported (25, 26) . Further study will be necessary to determine whether Smad3 agonists might be useful for the prevention or treatment of metastasis in specific cancer subpopulations.
